Share Price:

APNASPENAspen Pharmacare Hldgs15260-165 (-1.07%)
Our Response to Covid
Country Sites

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

Year: 2012

30 000 ARV packs delivered in Limpopo

Following discussions between the health Minister Dr Aaron Motsoaledi and Aspen Pharmacare Senior Executive Mr Stavros Nicolaou in Johannesburg, Aspen Pharmacare released 30 000 packs of Tenofovir (TDF) for the Limpopo depot earlier today. Further releases to this province are expected during the course of next week. Aspen Pharmacare is one of the two (2) companies supplying ARVs to government hospitals. Reports have recently suggested that there were shortages that were being encountered in the availability of ARVs. In a media conference in Johannesburg yesterday, the health Minister dispelled these reports of complete unavailability of these drugs, indicating instead that there was a decline in stock-levels which did not necessarily translate in patients not getting their ARVs. Health Minister has expressed his happiness at news that stock-levels in the Limpopo depot have been increased. “It’s an important development and it actually demonstrates our commitment to ensuring that at no point are our patients compromised. We are continuously monitoring the situation on a daily basis and I must commend Aspen for their quick response in dealing with the situation”, said the health Minister. For media enquiries please contact: Fidel Hadebe – Department of Health: 079 517-3333 or Stavros Nicolaou – Senior Executive: Aspen Pharmacare: 082 458-3135. Issued by the Department of Health

Statement by Aspen on the reported Tenofovir (TDF) public sector supply shortages

Statement by Aspen on the reported Tenofovir (TDF) public sector supply shortages Johannesburg: Since March this year there have been sporadic reports of Tenofovir (TDF) supply shortages in certain provinces and hospitals where patients are receiving ARV treatment. These reports seem to have manifested again this week and some allegations have emerged that the contracted TDF suppliers are in part responsible for these shortages. Aspen, as the Southern Hemisphere’s largest Pharmaceutical Manufacturer and the leading supplier of ARV’s to both the SA private and public sector can in no way condone these shortages, even if it is to a small group of patients and accordingly the company wishes to publicly clarify the following: • At a press briefing earlier today Minister of Health, Dr Aaron Motsoaledi confirmed that the National Department of Health (NDOH) had checked all 10 depots nationally and all 10 have TDF. • Aspen has the state contract to supply 70% of the required state volume for TDF for a two year period, commencing on 1 January 2011 and ending on 31 December 2012. It is required to deliver within 6 weeks of confirmation of received orders. • Initial offtakes for TDF during the first year of the tender contract were extremely low, with monthly orders placed on Aspen averaging around 250 000 monthly treatment packs. This was largely because donor fund procured TDF product displaced much of the tender volumes. • This donor fund procured inventory ran out by December 2011 and it became necessary for the current suppliers to respond, by immediately scaling up production. • The transition from donor stock to state procured TDF was not a smooth transition, with some provinces and institutions underforecasting demand and/or placing orders either erratically or only once stock levels had dwindled significantly. Consequently, some institutions remained well stocked, whilst others ran into problems. • Despite this, For example, NDOH’s forecast for 70% of the volume over the past 3 months from March to May 2012 required Aspen to supply 668 000 packs per month or 2 million packs for this period. Over this 3 month period, Aspen has supplied 2,4 million packs, exceeding its contractual requirement by more than 400 000 packs. This averages out to approximately 860 000 packs per month. Aspen has been advised by the NDOH that it is needed to over-supply on its contractual commitment because the supplier required to supply the other 30% of the TDF tender is unable to do so. Aspen has accordingly stepped in and is manufacturing in excess of its contractual requirements. By way of example, Aspen has supplied 1,140 million treatment packs for the month of May to the NDOH, exceeding by 350 000 packs its monthly contractual requirement. • As this crisis began to unfold, Aspen acting in consultation with the NDOH, has been able to step up both its raw material imports and allocation of manufacturing capacity to meet this increased demand. It has been able to do so with requisite flexibility and in a short space of time. • Given the current situation, Aspen will continue to commit the required capacity from now until the end of the tender period, to ensure that it not only meets its own tender volume obligations, but it is able to step in and supply the quantities that other suppliers are unable to. • Aspen views supply security and the maintenance of the integrity of the South African Public ARV programme as a National imperative. It also views its commitment to supply timeously and according to its committed quantities with equal importance. To this end, Aspen has an excellent track record in the manufacture, supply and delivery of ARV’s to the SA Government. This is not the first time Aspen has had to step in to supply where importers who had won the contract for other ARVs have been unable to supply in the current contract period. This has been the case, for example, where Aspen has had to take over supply for Stavudine 30mg and Lamivudine 150mg in the current two year contract period. Aspen has thus continued to supply on its own commitments, in addition to that where other suppliers have been unable to supply. In conclusion, Aspen is able to confirm that it is presently meeting both its contractual terms and supply volumes for TDF that it is required to in terms of the current ARV tender. The Company can also confirm that it presently has no backorder for TDF, meaning that all remaining orders in the system are within the 6 week delivery period. The company will supply around 1,1 million packs in June 2012, which will again exceed monthly NDOH forecast by 400 000 units.

Stephen Saad raises R10 million for children

Health Minister supports Stephen Saad’s initiative as he raises R10m for children Durban: Health Minister Dr Aaron Motsoaledi’s support of the Sifiso Nxasana Paediatric Trust for the Children of Africa (“the Trust”), which is raising funds for paediatric hospitals, is paying off with R10 million already raised. The campaign was recently launched by pharmaceutical entrepreneur Stephen Saad, Aspen Group Chief Executive, as a personal commitment to making a quality healthcare difference for all children. Dr Motsoaledi demonstrated his support of the campaign by leading the field of cyclists alongside Saad in the inaugural 240 km Aspen Trans Karoo mountain bike challenge from Ceres to Sutherland in the Western Cape. Saad said “The Minister’s commitment to establishing and enhancing healthcare facilities for children has been amazing. His enthusiastic participation in the event proves that he truly cares about their needs and he demonstrated this with his peddling power.” Dr Motsoaledi supports the urgent need for public-private partnerships in addressing the shortage of paediatric healthcare. “The challenges confronting us are huge and government alone cannot adequately address them. We are glad that Aspen has identified this gap and are sharing our vision of ensuring that all children, regardless of their socio-economic status have access to quality paediatric care in our country”, said the health Minister. “We have an obligation to care for our children and we’re calling on local and offshore businesses who have an interest in Africa to support the Trust. We’re grateful for the pledges of R10 million received so far and I’m confident that we can raise so much more,” said Saad who has challenged big businesses to follow the Health Minister’s lead and make a meaningful paediatric difference through the Trust. Saad completed the race just short of 16 hours and said that it was a fabulous feeling to cross the finish line, knowing that his efforts would make a huge healthcare difference for children. Former South African Iron Man Raynark Tissink won the race with Hannele Steyn being the first lady to cross the finish line. The 18½ hour race route reached its highest point at 185km, with a 724m climb over 6km on a 12% gradient. South Africa needs more paediatric hospitals. There are only 4 in Africa to serve some 450 million children. The only such facility in South Africa is the Red Cross Children’s Hospital in Cape Town. Canada has 23, Australia has 19 and there are 20 in Germany. The two primary beneficiaries of the Trust have been identified as the Nelson Mandela Children’s Hospital and the Kwa-Zulu Natal Children’s Hospital. The Trust was established to support the Long Ride for Sifiso Campaign following the untimely passing of Sifiso Nxasana, son of Judy Dlamini and her husband Sizwe Nxasana, CEO of FirstRand Ltd. Judy is the Chairman of Aspen. To support the Trust, download and complete the Sifiso Nxasana Long Ride Campaign pledge form on www.transkaroomtb.co.za.

Stephen Saad completes grueling 240km mountain bike challenge

Stephen Saad completes grueling Aspen Trans Karoo challenge Sutherland, Western Cape: Stephen Saad, Aspen Group Chief Executive, completed the grueling inaugural 240km Aspen Trans Karoo mountain bike challenge in 15hrs59min30sec in a bid to raise funds for desperately needed paediatric healthcare facilities in South Africa. Raynard Tissink won the endurance race in a time of 9hrs42min. The challenge started at Ezelfontein in Ceres and stretched to Sutherland in the Western Cape. Tissink completed the race some 4 minutes head of Timo Cooper and Hannes Hanekom who crossed the line in second and third place respectively. Hannele Steyn was the first lady home with a time of 11hrs32min44sec. Health Minister Dr Aaron Motsoaledi and Stephen Saad, Aspen Group Chief Executive started the grueling race together in support of healthcare facilities for children in South Africa. Saad took on the challenge to raise funds for children’s hospitals through the Sifiso Nxasana Paediatric Trust for the Children of Africa (“the Trust”), which Stephen recently established. The initiative was fully embraced by Dr Motsoaledi as was demonstrated through his race participation. Saad said, “The race was a beast but an incredible endurance challenge as I’d never cycled this distance before. It was a fabulous feeling to cross the finish line, knowing that my efforts would make a huge healthcare difference for children, irrespective of their socio-economic backgrounds.” He completed the race together with team Aspen cyclists Chris Mortimer, a non-executive director of Aspen, Rob Scott and Rick Kennedy. The 18½-hour race route reached its highest point at 185km, with a 724m climb over 6km on a 12% gradient. Additional first place race results included: Two man solo team: Mathew Wentworth & Hudson Chevallier. Two ladies team: Anneke Jacobs and Alma Colyn. Two mixed team: Neil and Belinda van Tonder. Four man team: Ben Mathewson, Craig Lillie, John Andrew and Jason Bailey. Four mixed team: Jean Goussard, Francois Boonzaier, Andre du Toit and Hannelle Smith. Saad has been calling on organisations that have an interest in Africa to support the Trust through sponsorship or donations. The two primary beneficiaries are the Nelson Mandela Children’s Hospital and the Kwa-Zulu Natal Children’s Hospital. The Trust was established to support the Long Ride for Sifiso Campaign following the untimely passing of Sifiso Nxasana, son of Judy Dlamini and her husband Sizwe Nxasana, CEO FirstRand Ltd. Judy is the Chairman of Aspen. Africa presently has 4 specialist paediatric facilities to care for some 450 million children with the only local facility being the Red Cross Children’s Hospital in Cape Town. In contrast, there are 23 children’s hospitals in Canada, 19 in Australia and 20 in Germany. To support the Trust, download and complete the Sifiso Nxasana Long Ride Campaign pledge form on www.transkaroomtb.co.za.

Stephen Saad & Health Minister cycle for children’s hospitals

Ceres, Western Cape: Health Minister Dr Aaron Motsoaledi and Stephen Saad, Aspen Group Chief Executive started the grueling inaugural 240km Aspen Trans Karoo mountain bike challenge together earlier today to enhance healthcare for children in South Africa. Stephen said, “Raising funds for paediatric healthcare facilities through the Sifiso Nxasana Paediatric Trust for the Children of Africa (“the Trust”) has been the primary motivator for participating in this race. We are delighted that Dr Motosaledi has embraced our vision to provide enhanced access to quality healthcare for all children – irrespective of their socio-economic background.” Dr Motsoaledi supports the urgent need for public-private partnerships in addressing the shortage of paediatric healthcare. “The challenges confronting us are huge and government alone cannot adequately address them. We are glad that Aspen has identified this gap and are sharing our vision of ensuring that all children, regardless of their socio-economic status have access to quality paediatric care in our country”, said the health Minister. Saad has been calling on organisations that have an interest in Africa to support this worthy cause through sponsorship or donations. “The children of Africa need the support of large organisations. The response to this initiative has been encouraging and we hope to make a meaningful contribution to our two primary beneficiaries, the Nelson Mandela Children’s Hospital and the Kwa-Zulu Natal Children’s Hospital.” Africa presently has 4 specialist paediatric facilities to care for some 450 million children with the only local facility being the Red Cross Children’s Hospital in Cape Town. In contrast, there are 23 children’s hospitals in Canada, 19 in Australia and 20 in Germany. The Trust was established to support the Long Ride for Sifiso Campaign following the untimely passing of Sifiso Nxasana, son of Judy Dlamini and her husband Sizwe Nxasana, CEO FirstRand Ltd. Judy is the Chairman of Aspen. Judy and Sizwe were in attendance together with their extended families to pay tribute to Sifiso and to encourage the 220 cyclists who set off in pleasant conditions on the 240 km challenge from Ezelfontein in Ceres to Sutherland in the Western Cape. Judy said that it was a fitting opportunity to demonstrate support for the establishment and enhancement of paediatric healthcare for Southern Africa’s children. Former President Nelson Mandela’s living legacy is to build a state-of-the-art children’s hospital that will provide paediatric care for all children across Africa. The Kwa-Zulu Natal Children’s Hospital is also being re-established to provide for the regional healthcare needs of approximately 3 million children. To support the Trust, download and complete the Sifiso Nxasana Long Ride Campaign pledge form on www.transkaroomtb.co.za.

Aspen announces multi-territory acquisition of GSK OTC products for R2.1 billion

Aspen Pharmacare Holdings Limited (“Aspen”) (Incorporated in the Republic of South Africa) Registration Number 1985/002935/06 Share code APN – ISIN: ZAE000066692 (“Aspen Holdings”) ASPEN ANNOUNCES MULTI-TERRITORY ACQUISITION OF GSK OTC PRODUCTS FOR R2.1 BILLION Durban, South Africa: Aspen Holdings is pleased to announce that the Aspen Group (“Aspen”) has reached agreement with GlaxoSmithKline plc (“GSK”) for the acquisition of a portfolio of established over-the-counter (“OTC”) products (“the products”) in selected territories including South Africa, Australia and Brazil. The deal is valued at GBP 164 million (ZAR 2.1 billion at ZAR 12.6/GBP). Stephen Saad, Aspen Group Chief Executive said, “The products acquired through these transactions are an excellent geographic fit with Aspen’s existing footprint and will allow for significant strengthening of Aspen’s OTC offering in all of the territories concerned. The products have considerable established brand equity, which Aspen intends to leverage through increased promotion and plans to expand through line extensions. The transactions will also provide impetus in territories where Aspen is seeking to grow critical mass such as Latin America and South East Asia.” The deal comprises two transactions (“the transactions”): The acquisition by Aspen Holdings of the products sold in the territories of South Africa, Namibia, Botswana, Swaziland, Lesotho, Zambia and Zimbabwe for GBP 20 million (ZAR 252 million at ZAR 12.6/GBP) (“the Southern Africa transaction”); and The acquisition by Aspen Global Incorporated, a wholly owned subsidiary of Aspen Holdings incorporated in Mauritius, of the products sold in the rest of the world, but excluding the territories of North America and Europe (which are the subject of separate transactions concluded between GSK and third parties), for GBP 144 million (ZAR 1.8 billion at ZAR 12.6/GBP (“the Rest of the World transaction”). The Southern Africa transaction is subject to, amongst others, the following conditions precedent: The approval of the South African competition authorities; and The approval of the Financial Surveillance Department of the South African Reserve Bank. In addition, the Southern Africa transaction in respect of Namibia and Swaziland only, is subject to and conditional upon the approval of the respective competition authorities in those countries. The effective date of the Southern Africa transaction will be the last business day of the calendar month in which the last of the applicable conditions precedent is fulfilled. The Rest of the World transaction is unconditional and is effective from 1 May 2012 save in respect of: the product, Zantac, which is marketed, distributed and sold in Australia and New Zealand which is subject to the approval of the Australian competition authorities; the portion of the Rest of the World transaction relating to Kenya which is subject to the approval of the Kenyan competition authorities; and the portion of the Rest of the World transaction relating to Tanzania which is subject to the approval of the Tanzanian competition authorities. (collectively, “the Rest of the World conditions”). The transaction value of the products which are subject to the Rest of the World conditions is GBP 23.1 million (ZAR 291 million at ZAR 12.6/GBP). The elements of the Rest of World transaction which are subject to the Rest of the World conditions will be effective on the last business day of the month in which the respective Rest of the World conditions are fulfilled. In terms of the transactions the marketing and distribution of the products will transition from GSK to Aspen over periods of time varying by country. Existing manufacturing arrangements for the products will be assumed by Aspen. Funding The transactions will be funded from existing cash resources, existing credit facilities and new debt, the latter funding approximately 50% of the transaction. Arrangements for the raising of the new debt have been finalised. The Products: The products comprise well established OTC brands of proven performance. The main areas of therapeutic treatment of the products are analgesic, gastro-intestinal and respiratory. Other areas covered include dermatology, infant care, vitamins and minerals. The leading products are recognised household brands such as Phillips Milk of Magnesia, Dequadin, Solpadeine, Cartia, Zantac and Borstol. GSK reports that the products which are the subject of the transactions recorded revenue of GBP 59.3 million in calendar 2011. In accordance with Aspen’s segmental reporting this revenue is split as follows: Asia Pacific: GBP 21.4 million; South Africa: GBP 7.3 million; Sub-Saharan Africa: GBP 5.0 million; and International: GBP 25.6 million (of which GBP 17.0 million is in Latin America). Aspen expects the transactions to be earnings accretive from the outset. GSK’s announcement of the transaction can be accessed from their website by clicking on http://www.gsk.com/media/index.htm. Issued by: Shauneen Beukes, Shauneen Beukes Communications Tel: +27 (012) 661-8467 : Cell: +27 82 389 8900 On Behalf Of: Stephen Saad, Aspen Group Chief Executive Tel: +27 (031) 580-8603 Gus Attridge, Aspen Deputy Group Chief Executive Tel: +27 (031) 580-8605 Roshni Gajjar, Aspen Investor Relations Tel: +27 (041) 407-2952 : Cell: +27 82 879 1826

Stephen Saad raises funds for children’s hospitals

Durban: South African pharmaceutical social entrepreneur, Stephen Saad, has embarked on a personal initiative to help raise funds for paediatric healthcare facilities in South Africa. Stephen Saad said, “I fully embrace the social obligation to raise funds for the healthcare needs of underprivileged children and I’m calling on all organisations that have an interest in Africa, to support this worthy cause through sponsorship or a donation. The Sifiso Nxasana Paediatric Trust for the Children of Africa (“the Trust”) has been established for this purpose. On April 28, I’ll be cycling in the grueling 24 hour – 240km Trans Karoo mountain bike challenge from Ceres to Sutherland to help raise funds for the establishment and enhancement of children’s hospitals.” Stephen’s motivation to do the challenge is based on his belief that all children deserve quality care and as a dedication to the sad and untimely passing of Sifiso Nxasana. Sifiso was the son of Judy Dlamini and her husband Sizwe Nxasana, CEO FirstRand Ltd. Saad’s Long Ride for Sifiso Campaign, which will raise funds for the Trust, has been welcomed and endorsed by the Minister of Health, Dr Aaron Motsoaledi, who said “Every effort must be made to ensure that future generations are provided with healthcare facilities that meet their needs – irrespective of their economic or social background. This Trust will demonstrate the support of local and international businesses alike towards caring for children who have previously not had access to specialist medical services. It is hoped this is the start of a closer co-operation between the public and private sectors in order to drive improved healthcare for all.” There is a desperate need for quality pediatric healthcare in South Africa. Presently there are only 4 specialist paediatric facilities in Africa to care for some 450 million children. The only local facility is the Red Cross Children’s Hospital in Cape Town. This is a shocking comparison to the 23 children’s hospitals in Canada, 19 in Australia and 20 in Germany. Two beneficiaries have provisionally been earmarked for the Trust, namely the Nelson Mandela Children’s Hospital and the KwaZulu-Natal Children’s Hospital. Former President Nelson Mandela’s living legacy is to build a state-of-the-art children’s hospital that will provide paediatric care for all children across Africa. The Kwa-Zulu Natal Children’s Hospital is also being re-established to provide for the regional healthcare needs of approximately 3 million children. The Trust aims to: Make a meaningful contribution in addressing paediatric public healthcare needs, particularly for children from historically disadvantaged or resource constrained backgrounds. Improve access and affordability to paediatric care, particularly in those areas that requires specialist paediatric care. Ensure sustainability and appropriate resourcing of these facilities. Develop adequate management capacity and human resourcing in these facilities. Contribute to the overall strengthening of the South African Public Healthcare system. Provide hope to those children, who would otherwise have limited or no prospect of survival. Saad’s philanthropic spirit concerning the healthcare needs of the people of Africa can be traced back to the start of the century, when he convinced multinational pharmaceutical companies to release the patents held on anti-retroviral (ARV) medication in order to provide affordable treatment to the millions of HIV/Aids patients on the African continent. Saad succeeded in his pioneering endeavor, and in 2003 Aspen launched the first generic ARV to provide hope to those suffering from this disease. Currently some 900 000 patients across Africa take an Aspen ARV daily. To support the Trust, download and complete the Sifiso Nxasana Long Ride Campaign pledge form on www.transkaroomtb.co.za.

Aspen increases revenue by 31 percent

Johannesburg – JSE Ltd listed Aspen Pharmacare Holdings Limited (Apn), Africa’s largest pharmaceutical manufacturer, has announced pleasing results for the interim period ended 31 December 2011, once again proving Aspen’s resilience across its global businesses. Group Performance Revenue from continuing operations rose by 31 percent to R7.5 billion (R5.7 billion). Operating profit before amortisation from continuing operations adjusted for specific non-trading items (“EBITA”), improved by 32 percent to R2.2 billion (R1.6 billion) Diluted normalised headline earnings per share (DNHEPS) from continuing operations increased by 22 percent to 308.1 cents (253.3 cents). Growth in earnings was affected by higher funding costs on the debt raised to acquire the pharmaceutical division of Sigma Pharmaceuticals Limited in Australia (“the Sigma business”) in January 2011. Stephen Saad, Aspen Group Chief Executive said, “The Group’s strong showing for the period was the result of excellent performances across the offshore territories with Asia Pacific leading the way. The Asia Pacific region increased its contribution to Group EBITA from 8% to 34% in the current period.” South African Business Revenue in the South African business was 11% down at R2908 million with the Pharmaceutical division declining 9% and the Consumer division declining 19%. Despite the headline results, the underlying performance of the Pharmaceutical division was good. Annualised revenue growth measured by IMS at 31 December 2011 indicated Aspen’s generic products increased by 16.2% The contributing factors to the performance reversal were largely one-offs in nature and, where appropriate, mitigating actions have been taken which will benefit the business going forward. These factors have been well communicated and are as follows: The Pharmaceutical division’s two biggest products, Seretide and Truvada, both came under pressure from generic substitutes for the first time in the second half of the 2011 financial year; Offtakes under the antiretroviral (“ARV”) tender were significantly lower than expected during 2011 as the South African government used donor sponsored products rather than accessing the tender awarded; Aspen retained its leading stake in the recently awarded public health ARV tender which commenced in January 2011. Aspen has both the lower volume share of this tender and reduced pricing on the prior tender. Given the supply of donor funded stock to date, these sales decreases have not been mitigated by the anticipated increases from expanded coverage; The license with Pfizer for a range of infant milk products which had contributed revenue of approximately R250 million per annum to the Consumer division expired; and Production for most of July was lost due to a union led strike. EBITA was 17% lower at R841 million. Profit margins came under pressure due to reduced production volumes as a result of the poor ARV tender offtake, the cost of production lost through the strike, inflationary increases in wages and energy, as well as the weaker Rand. The revenue lost on the genericisation of Seretide has been recovered by Aspen’s own generic, Foxair. The December 2011 launch of Tribuss, the first generic triple combination ARV to market, provides the opportunity to regain lost revenue incurred on Truvada’s genericisation. The Consumer division performance was disappointing. It was hoped that securing the major portion of the public healthcare tender for infant milk formula would help offset the loss of the Pfizer license. However, volumes ordered by the state since the tender was awarded have been erratic, and sustainable demand has yet to be established. Investment in capital projects at the production facilities is ongoing. Major projects underway include adding tableting capacity in Port Elizabeth, moving liquids manufacture to East London and introducing new technologies in Cape Town. Asia Pacific Business As anticipated, the Asia Pacific business was the leading growth driver for the Group. Revenue of R2859 million is more than three times greater than the comparative period whilst EBITA has grown from R133 million to R736 million. The EBITA achieved in the past six months is 15% greater than that achieved in the full 2011 financial year. The acquisition of the Sigma business has clearly played a material role in the exponential growth recorded by the region. The successful merger of the Sigma business with the pre-existing Aspen business in Australia has been fundamental to this achievement. The merged business is operating as a single unified structure allowing the realisation of synergies and efficiencies. Together with the delivery of the first procurement savings, this has translated into a steady improvement in operating profit margins. The strong market position of the Australian business has assisted it in concluding a co-marketing agreement with Lilly for its market leading psychotic disorder product, Zyprexa, and the generic of the molecule, Olanzapine. The consolidation and rationalisation of the Australian facilities has continued. The Tennyson site has been sold. The Croydon and Noble Park sites are in the process of phased closure. Production is now centred at the Dandenong facility and supported by the Baulkham Hills facility. Expansion of Aspen’s presence in South East Asia is receiving attention from the regional management team. The newly established business in the Philippines is in full operation with close to 100 sales representatives deployed. International Business The International business increased revenue by 5% to R1 443 million and raised EBITA by 17% to R455 million. Latin America was a leading contributor to the growth with sales to customers in that region rising 23% while revenue in the Rest of the World territories remained unchanged on the prior year. The widening of profit margins can be attributed to a favourable position in the cycle of transitioning global brands to Aspen distribution as well as the realisation of the first savings in the global brands cost of goods reduction programme. Sub-Saharan Africa Gross revenue improved by 25% to R835 million and EBITA added 23% to R136 million in Sub-Saharan Africa. The primary driver in these positive results was the GSK Aspen Healthcare for Africa collaboration, which performed strongly in Nigeria and French West Africa. Prospects Although the South African business will continue to face the influence of unfavourable events in the second half of… Continue reading Aspen increases revenue by 31 percent

Closed Period

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.

Corporate

Our career opportunities are across the corporate spectrum, including Human Capital, Digital Technology, Legal, and Risk & Sustainability. Our employees are given the opportunity to hone their skills and develop the experience of excellence in their chosen field in the pharmaceutical industry.

View our teams below:

Human Capital
Legal

Supply Chain

Treasury
Ethics & Compliance
Risk & Sustainability
Digital Technology

Tax